Schond Greenway
Director of Finance/CFO presso MIND MEDICINE (MINDMED) INC.
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Schond L.
Greenway is currently the Chief Financial Officer at Mind Medicine (MindMed), Inc. He previously worked as the Executive Director-Strategy & IR at Halozyme Therapeutics, Inc. from 2013 to 2016.
He also held the position of VP-Investor Relations & Strategic Planning at DURECT Corp.
and Vice President-Healthcare at Barclays Capital, Inc. Mr. Greenway was the VP & Global Head-Investor Relations at Mesoblast Ltd.
from 2016 to 2021.
He then worked as the Chief Financial Officer & Treasurer at Avalo Therapeutics, Inc. from 2021 to 2022.
Mr. Greenway received his undergraduate degree from Florida A&M University and his MBA from the University of Virginia Darden School of Business.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 25/03/2024 | 211 057 ( 0.30% ) | 2 M $ | 31/03/2024 |
Posizioni attive di Schond Greenway
| Società | Posizione | Inizio |
|---|---|---|
| MIND MEDICINE (MINDMED) INC. | Director of Finance/CFO | 23/05/2022 |
Precedenti posizioni note di Schond Greenway
| Società | Posizione | Fine |
|---|---|---|
| AVALO THERAPEUTICS, INC. | Director of Finance/CFO | 14/02/2022 |
| MESOBLAST LIMITED | Investor Relations Contact | 01/02/2021 |
| HALOZYME THERAPEUTICS, INC. | Investor Relations Contact | 01/01/2016 |
| DURECT CORPORATION | Public Communications Contact | - |
Barclays Capital, Inc.
 Barclays Capital, Inc. Investment Banks/BrokersFinance Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team. | Corporate Officer/Principal | - |
Formazione di Schond Greenway
| Florida A&M University | Undergraduate Degree |
| University of Virginia Darden School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| DURECT CORPORATION | Health Technology |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| MESOBLAST LIMITED | Health Technology |
| AVALO THERAPEUTICS, INC. | Health Technology |
| MIND MEDICINE (MINDMED) INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Barclays Capital, Inc.
Barclays Capital, Inc. Investment Banks/BrokersFinance Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team. | Finance |
- Borsa valori
- Insiders
- Schond Greenway
